| Previous Close | 0.1800 |
| Open | 0.1570 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.1570 - 0.1800 |
| 52 Week Range | 0.1400 - 0.4700 |
| Volume | 91,455 |
| Avg. Volume | 156,664 |
| Market Cap | 28.628M |
| Beta (3Y Monthly) | -1.86 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0780 |
| Earnings Date | May 13, 2019 - May 17, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
SUWANEE, GA, April 10, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV) is pleased to provide an update regarding the Company’s regulatory status in the worldwide sales and distribution of the company’s medical devices. In addition to our long-standing presence in Europe, Canada, and South Korea, SANUWAVE® has been extremely active adding major and emerging medical device markets to our portfolio. In addition to countries in which SANUWAVE is making its presence known, we expect to expand this list with 3 – 4 more registrations in 2019. We are actively engaged in the registration and licensing process in Asia with Indonesia, Singapore, and Taiwan (for dermaPACE®). Closer to home, SANUWAVE is working on licensing in Mexico, Costa Rica, Panama, and Brazil. These processes are time-consuming, and we are anticipating successful completion to most, but not all, of these market applications.
SANUWAVE (SNWV) announced Q4 / full-year 2018 financial results and provided a business update. Continued progress with putting the U.S. commercialization strategy in place means domestic revenue should begin to accelerate later this year. Meanwhile, expansion of the international footprint and increasing sales in existing territories should benefit OUS revenue growth.
Suwanee, GA, April 04, 2019 -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCBB: SNWV) (www.sanuwave.com): SANUWAVE® is pleased to announce initial enrollment beginning this.
SUWANEE, GA, April 02, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV), an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, received United States Patent US 10,238,405 on March 26, 2019 entitled “Blood Vessel Treatment with Intracorporeal Pressure Shock Waves” which has a patent life up to January 2032 from the U.S. Patent and Trademark Office (USPTO). This U.S. patent includes eight (8) claims related to the special construction of the intracorporeal shockwave apparatuses/systems comprising of a catheter size fit within a blood vessel, with one or multiple shockwave applicators that include shockwave generation sources disposed within an ellipsoidal reflector oriented perpendicular to the catheter longitudinal central axis of symmetry, which can produce focused shockwaves oriented towards vessel’s wall where the plaques are forming.
SUWANEE, Ga., March 29, 2019 -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB: SNWV) will report financial results for the year ended December 31, 2018 with the SEC on.
SUWANEE, GA, March 27, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV) announced today that the Company will host a conference call on Friday, March 29, 2019, beginning at 10AM Eastern Time to discuss the 2018 financial results, provide a business update and answer questions. SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration.
SUWANEE, GA, March 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV) an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, announces the latest edition of The Pulse, Spring 2019, a newsletter which highlights a recent synopsis of events including the first installment of 11 Minutes with Shri, a video interview between SANUWAVE President, Shri Parikh and Dr. David Armstrong, Professor of Surgery and Director of the Southwestern Academic Limb Salvage Alliance (SALSA) at the Keck School of Medicine at USC. 11 Minutes with Shri is a video series that will continue to showcase experts and Key Opinion Leaders involved in the treatment of diabetic foot ulcers.
March 14 – 17, 2019 at KIMES in Seoul, Korea. SANUWAVE will take the opportunity to showcase its successful disruption in the medical device industry at a venue where 1,200 domestic and overseas manufacturers present new technology and products. KIMES is a fantastic place for networking and for SANUWAVE to share its impact in the fast-developing medical market. April 26- 27, 2019 at MWCM in Greensboro, NC. SANUWAVE is currently making arrangements to attend The Modern Wound Care Management conference which provides the highest quality continuing medical education experience to all clinicians who care for patients with chronic wounds. SANUWAVE, like others in attendance, focuses on improved patient outcomes by maintaining the most modern and effective management techniques.
SUWANEE, GA, March 06, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV), an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, is excited to announce winning the JWC’s (Journal of Wound Care) 2019 Innovation in Chronic Wound Healing Award for dermaPACE® pressure shockwave for wound management. The JWC is the definitive wound-care journal and the leading source of up-to-date research and clinical information on everything related to tissue viability.
SANUWAVE (OTCQB: SNWV) has the potential to be one of these companies. Trading with a market cap of just under $30 million, SNWV is on the cusp of owning the next blockbuster in the diabetes care market. Focused on the treatment of diabetic foot ulcers, also known as DFUs, the company is embarking on an industry with incredible market potential.
Uptick Newswire Stock Day Podcast welcomed SANUWAVE Health, Inc. (SNWV) (“the Company), a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. CEO and Chairman, Kevin A. Richardson, joined Stock Day host Everett Jolly. To begin the interview Jolly asked Richardson to share the Company’s goals and expectations for 2019.
To achieve this long-term objective, we have broken down the crucial steps along the way, usually five steps per year, and we share them with you, our investors, so you can measure our progress against our ultimate goal. As a company, we have financial goals, but our top goal remains improving patients’ quality of life and ensuring everything we do cascades from this.
SUWANEE, GA, Dec. 27, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV) an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, announces the last installment of its blog for the year 2018, “SHOCK THIS” on its website www.sanuwave.com. As with previous installments, this interview was led by SANUWAVE's Chief Science and Technology Officer, Dr. Iulian Cioanta, titled "Seasoned Executive Shares his Views on Shockwave Technology, its Past, Present, and Future. In 2018, our focus with the blog continues to be on opinions expressed in interviews with pioneers and influential personalities who’ve added significant contributions towards advancing wound care and the use of shockwave technology. Therefore, in this new blog, SANUWAVE presents an interview with Shri Parikh, who joined SANUWAVE six months ago, as the President of Healthcare Division. The interview emphasizes Shri’s personality, background, ideas, and his vision on the commercialization of dermaPACE® System for diabetic foot ulcers (DFUs), in capitalizing on existing shockwave systems offered by the company and in the same time advancing SANUWAVE’s shockwave technology into new medical verticals.
SUWANEE, GA, Dec. 20, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV) an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, announces another installment of its blog, “SHOCK THIS” on its website www.sanuwave.com. The blog installments continue to be authored by SANUWAVE's Chief Science and Technology Officer, Dr. Iulian Cioanta, and this most recent one is titled "After Six Months with SANUWAVE Health, Inc., Shri Parikh, the President of Healthcare Division, Offers His Personal Perspective on the Business and His New Role with SANUWAVE". In 2018, our focus with the blog continues to be on opinions expressed in interviews with pioneers and influential personalities who’ve added significant contributions towards advancing wound care and the use of shockwave technology. Therefore, in this new blog, SANUWAVE presents an interview with Shri Parikh, who joined SANUWAVE six months ago, as the President of Healthcare Division. The interview emphasizes Shri’s personality, background, ideas, and his vision on the commercialization of dermaPACE® System for diabetic foot ulcers (DFUs), in capitalizing on existing shockwave systems offered by the company and in the same time advancing SANUWAVE’s shockwave technology into new medical verticals.
· U.S. patent number US 10,053,376 entitled “Acoustic Pressure Shock Wave Devices and Methods for Fluids Processing” was issued on August 28, 2018 and has an effective life through December 2036. The patent includes twenty claims relating to the use of shockwaves for removing particulate matter from contaminated waters. · U.S. patent number US 10,058,340 entitled “Extracorporeal Pressure Shock Wave Devices with Multiple Reflectors and Methods for Using These Devices” was issued on August 28, 2018 and has an effective life through November 2032. The patent includes twenty claims relating to the use of extracorporeal shockwaves, generated from multiple reflectors for cardiovascular applications, orthopedic afflictions, infection elimination, and stem cells stimulation, proliferation and differentiation.
SUWANEE, GA, Dec. 07, 2018 -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB: SNWV) SANUWAVE is excited to announce attendance at the 5th annual Innovations In Wound Healing.
SUWANEE, GA, Dec. 04, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV) an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, announces the publication of the research that investigated the effects of dermaPACE® System (an Extracorporeal Shock Wave Technology (ESWT)) compared with Standard of Care in Diabetic Foot Ulcers (DFUs). The peer reviewed article, titled “Diabetic foot ulcer treatment with focused shockwave therapy: two multicentre prospective, controlled, double-blinded, randomised phase III clinical trials,” by Robert Snyder, DPM, Robert Galiano M.D., Perry Mayer MB, Oscar Alvarez PhD, Lee C. Rogers DPM, will be published in the December 2018 issue of the Journal of Wound Care.
Q3 Results, Operational Update: Robust Int’l Revenue, U.S. Should Benefit from Tracking Code…. SANUWAVE (SNWV) reported financial results and provided a business update (on two consecutive Q3 earnings calls). Revenue has now grown on a sequential basis for the fifth consecutive quarter and is trending at an annual run rate of more than $3M.
Total Revenue Increase of 269%;Initial US treatments have begun, New President, Shri Parikh, to Discuss on Conference Call at 10 am SUWANEE, Ga., Nov. 20, 2018 -- via.
Product revenue for the third quarter of 2018 was approximately $260,000, up 67% from the third quarter of 2017. Product revenue for the nine month period was up 99% from the nine month period in 2017.
SUWANEE, GA, Nov. 14, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV) announced today that the Company will release financial results for the third quarter ended September 30, 2018 this week. The Company will also host a conference call on Thursday, November 15, 2018, beginning at 10AM Eastern Time to discuss the third quarter financial results, provide a business update and answer questions. SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures.
SUWANEE, GA, Oct. 31, 2018 -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB: SNWV) and Premier Shockwave, Inc. are pleased to announce that Premier Shockwave will exhibit at.